The aggressiveness of cancer care in the last three months of life: A retrospective single centre analysis

Psycho-Oncology

Volumn 16, Issue 9, 2007, Pages 863-868

  Braga, Sofia ^a   Miranda, Ana ^a   Fonseca, Rute ^a   Passos Coelho, J L ^a   Fernandes, Aires ^a   Costa, J D ^a   Moreira, António ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

Aggressiveness; Cancer; End of life care; Oncology; Palliative chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CARCINOMA; CANCER PALLIATIVE THERAPY; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DEATH; ESOPHAGUS CANCER; FEMALE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEALTH CARE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MELANOMA; METASTASIS; OVARY CARCINOMA; PANCREAS CARCINOMA; PROBABILITY; RETROSPECTIVE STUDY; SARCOMA; SOLID TUMOR; STOMACH CANCER; SYMPTOM; TERMINAL CARE; URINARY TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEMOGRAPHY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; RETROSPECTIVE STUDIES; TERMINAL CARE; TIME FACTORS;

EID: 34648843239     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.1140     Document Type: Article

References (31)

1. Earle CC, Neville BA, Landrum MB et al. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004;22:315-321.
2. Emanuel EJ, Yinong YX, Levinsky N et al. Chemotherapy use among medicare beneficiaries at the end of life. Ann Intern Med 2003; 138:639-644.
3. Browner I, Carducci M. Palliative chemotherapy: historical perspective, applications and controversies. Semin Oncol 2005; 32(2):145-155.
4. Doyle C, Crump M, Pintilie M et al. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 2001;19: 1266-1274.
5. Kornblith A. Does palliative care palliate? J Clin Oncol 2001; 19:2111-2113.
6. Gough IR, Furnival CM, Burnett W. Patient attitudes to chemotherapy for advanced gastro-intestinal cancer. J Clin Oncol 1981; 7:5-11.
7. Ellis PA, Smith IE, Hardy JR et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995;71:366-370.
8. Cullen MH, Billingham LJ, Woodroffe CM et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17:3188-3194.
9. Cullen M. 'Best supportive care' has had its day. Lancet Oncol 2001;2:173-175.
10. Cunningham D, Pyrh6nen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
11. Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 2001;19:1266-1274.
12. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15: 2403-2413.
13. Cormier Y, Eisenhauer E, Muldal A et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC): A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994;5:283-285.
14. Comis RL, Friedland DM. New chemotherapy agents in the treatment of advanced non-small cell lung cancer: An update including data from the Seventh World conference on Lung Cancer. Lung Cancer 1995; 12(suppl 2):S63-S99.
15. Casarett D, Abrahm JL. Patients with cancer referred to hospice versus a bridge program: patient characteristics, needs for care, and survival. J Chn Oncol 2001;19: 2057-2063.
16. Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol 2001;19:1455-1461.
17. Goodlin SJ, Winzelberg GS, Teno JM et al. Death in the hospital. Arch Intern Med 1998;158:1570-1572.
18. Emanuel EJ, Ash A, Yu W et al. Managed care, hospice use, site of death, and medical expenditures in the last year of life. Arch Intern Med 2002;162:1722-1728.
19. Barnato AE, McClellan MB, Kagay CR, Garber AM. Trends in inpatient treatment intensity among Medicare beneficiaries at the end of life. Health Serv Res 2004;39:363-375.
20. Wennberg JE, Fisher ES, Stuckel TA et al. Use of hospitals physician visits, and hospice care during the last six months of life among cohorts loyal to highly respected hospitals in the United States. Br Med J 2004;328:603-607.
21. Teno JM, Clarridge BR, Casey V et al. Family perspectives on end-of-life care at the last place of care. J Am Med Assoc 2004; 291:88-93.
22. Porkka K, Blomqvist C, Rissanen P et al. Salvage therapies in woman who fail to respond to first-line treatment with fluorouracil, epirrubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol 1994;12:1639-1647.
23. Meier DE, Back Al, Morrison S. The inner fife of physicians and care of the seriously ill. J Am Med Assoc 2001;286(23):3007-3014.
24. Turner J, Kelly B. The concept of debriefing and its application to staff dealing with life-threatening illness such as cancer, AIDS and other conditions. In Raphael B, Wilson JP. (eds). Psychological Debriefing: Theory, Practice and Evidence, UK: Cambridge University Press, 2000.
25. Burge F, Lawson B, Johnston G. Trends in the place of death of cancer patients, 1992-1997. Can Med Assoc J 2003;168:265-270.
26. Cintron A, Hamel MB, Davis RB et al. Hospitalization of hospice patients with cancer. J Palliat Med 2003; 6:757-768.
27. Earle CC, Neumann PJ, Gelber RD et al. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 2002; 20:1786-1792.
28. Ramirez AJ, Graham J, Richardsa MA, Cull A, Gregory WM. Mental health of hospital consultants: the effects of stress and satisfaction at work. Lancet 1996;347:724-728.
29. Llobera J, Esteva M, RifA J et al. Terminal cancer: duration and prediction of survival time. Eur J Cancer 2000; 36:2036-2043.
30. Christakis N, Lamont E. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. Br Med J 2000;320:469-473.
31. Glare P, Virik K, Jones M et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. Br Med J 2003;327:195-198.